Arcus Biosciences, Inc. (RCUS)

15.48 -0.15 (-0.96%) As of 11:05AM EDT. Market open.

Arcus Biosciences, Inc.

3928 Point Eden Way
Hayward, CA 94545
United States
510 694 6200
https://www.arcusbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 577

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Terry J. Rosen Ph.D.	Co-Founder, Chairman & CEO	1.21M	N/A	1960
Dr. Juan Carlos Jaen Ph.D.	Co- Founder & President	889.54k	N/A	1958
Mr. Robert C. Goeltz II	Principal Financial Officer & CFO	718.69k	N/A	1973
Ms. Jennifer A. Jarrett M.B.A.	Chief Operating Officer	883.69k	N/A	1971
Dr. Dimitry S.A. Nuyten M.D., Ph.D.	Chief Medical Officer	823.78k	N/A	1976
Dr. K. Christopher Garcia Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. Alexander Azoy	VP of Finance & Principal Accounting Officer	N/A	N/A	1976
Dr. Jonathan Yingling Ph.D.	Chief Scientific Officer	N/A	N/A	1969
Ms. Carolyn C. Tang J.D.	General Counsel & Corporate Secretary	603.2k	N/A	1979
Holli Kolkey	Vice President of Corporate Communications	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Corporate governance

Arcus Biosciences, Inc.’s ISS governance QualityScore as of 29 April 2024 is 10. The pillar scores are Audit: 7; Board: 10; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.